Artificial Intelligence Ushers in a New Era of Cost-Effective Clinical Trials 

4536
AI and machine learning have the potential to radically change the design and structure of clinical trials needed to approve new drugs and devices. Credit: Getty Images 

Contributed Commentary by James Streeter, Global Vice President Life Sciences Product Strategy, Oracle Health Sciences 

Clinical trials have changed significantly over the past several years. As drugs and devicesand the conditions they are trying to impacthave become increasingly more complex, so has the design and structure of clinical trials. But protocols are costly to change and identifying and enrolling the right patient cohorts is also no easy featespecially when rare diseases are the target. So, how are study teams keeping up with this rapid pace of change?  

Pharmaceutical companies, biotechs, and CROs have been incorporating technology at various stages of the trial process to address these challenges; but, ironically, some of these technologies have introduced new challenges such as the sheer volume of data that are being generated.  

Information and imagery from clinical visits, digitized voice notes, and the readings streaming in every second from patient-worn devices create a constant flow of data. Megabyte and gigabytes have given way to terabytes, petabytes, and zettabytes, overwhelming the ability of legacy systems and traditional human effort to manage. While it’s possible to capture and store all that information in data warehouses and data lakes, the question remains: How can this much data be cleaned, processed, managed, and evaluated to extract the insights that it holds?  

Artificial Intelligence for Efficient Design 

The answer lies in the application of artificial intelligence (AI) and machine learning (ML). AI can not only process data much faster than traditional methodsit can change the way the data are usedAlong with ML, which will teach the various systems to interpret and comprehend data so that technologies are continuously learningAI will make it possible to avoid design errors of the past and create entirely new trials of the future.  

To understand the full potential of AI and ML in clinical trials, first consider how they can help with protocol designHaving humans manually review prior studies, draw up designs, and handle endless amendments is a time-consuming and error-prone process. AI, in combination with ML, can do that work accurately and in far less time. By reviewing all the available historical data quickly and efficiently, these two technologies can unearth all the problems created from prior protocols and mid-study changes to fully optimize protocol buildingensuring past problems aren’t repeated.   

For example, many protocols define an age group that isn’t wide enough to recruit the number of patients needed for that specific indication. With the use of ML, expanded age groups can be identified to optimize recruitment based on learnings from previous studiesAutomating the building of trials in this way can eliminate obstacles like mid-study changes, misinterpretation of protocols, human errors, and other issues that ultimately delay getting drugs to market. The result is a more precise and betterdesigned protocol that will likely require minimal changespotentially saving millions of dollars in costs previously spent on change requests. 

Taming the Data Storm 

Once the trial is underway, AI becomes crucial to managing the flow of data. 

While traditional trials involve collecting data over a series of in-person clinic visitsthese events are no longer the only point at which patient data is gathered in a clinical trial. We’re moving to a world where traditional site visits will be supplemented by data from intelligent devices worn by patients that send readings multiple times a dayor even on a continuous basis. In the future, that information could be augmented with external data such as environmental factors like the weather, air quality, patient’s location or even their activity level at any moment.  

The use of real-world data in clinical trials represents a huge paradigm shift in the industry. Each enrolled patient could be creating hundreds or thousands to millions of data points a weekor even per day! That amount of data is far more information than humans can process or manage, and outsourcing or throwing more people at the problem is no longer sustainable or effective. But with AImassive amounts of data can be analyzed in record time.  Each piece of information in large data sets can be scrutinized to check for potential problems and compared to statistical norms to reject outlierswhile also identifying missing data pointsall while being performed at speeds that are not humanly possible  

Insights for Efficacy and Safety 

But AI can do more than that. Combined with ML, it can also interpret and draw insights from clinical dataWith information coming in on each patient at all times from all sides, AI will become the foundation of data interpretation. Not only can AI deal with structured data (such as that gathered in form fields)it can also process and interpret unstructured data, such as free-text, audio and visual information. For example, AI can “listen” to an examining doctor’s notes on a trial patientor even scan images and recognize them. This opens up whole new sources of insight that can be used to inform study teams and help them make decisions about the trial.  

Another important benefit of AI and ML’s ability to analyze and recognize data trends is that it can result in more robust safety reporting. Safety issues can often be subtle or go undetected until they become serious problems. AI can spot trends early on and allow safety teams to respond to them quickly and efficiently. It’s even possible to gather relevant safety data from outside the data collected as a part of the trial. For example, posts within patient discussion groups on social media could indicate a potential adverse event. While such surveillance could be done manually, the rate at which this information grows and spreads makes it extremely difficult for humans to keep pace And while tracking could be done with people performing basic online searches, this approach increases the human resources neededwhich can raise overall costs. AI can be used to automate this surveillance process and the triage of incoming safety cases faster and more effectively than a human attempting to do it manually could ever achieve  

Trials of the Future 

AI is already being incorporated into advanced cloud-based Life Sciences technology platforms to support trial design, data monitoring, and safety case management; however, we are just at the beginning of the AI era. Within a few years, AI and ML will be able to do things we can only imagine today. 

AI is the key to decentralized trialstrials in which a portion of patient data will come directly from the patients themselves, instead of through traditional methods during site visits. As patient pools grow smaller with “precision” and personalized medicinepatient recruitment becomes more challenging.  However, with the expansion of decentralized trials, people who were previously not able to participate in a trial because of their distance from the site will now be able to participate.  

We will also see the advent of “patient-less” trials, where we can use historical data rather than live data from people to conduct a trial. While it’s hard to imagine a trial without any patients, it is possible to imagine a trial in which the placebo arm is run on a virtual “placebo” group that is built on historic patient data.  This kind of design would not only lower costs but would also make trials more patient-centric and ethical by ensuring all the recruited patients receive the proposed treatment. 

AI and ML will only continue to develop and improve, especially when applied to cloud-based platforms that can draw on global data sources at scale. As these technologies become more widespread and further embedded into clinical trial platforms, they will usher in a new era of better, more efficient and effective trials that will reduce the cost of bringing new drugs to market, while speeding the process of developmenthelping to deliver lifesaving drugs to market to patients who are waiting in need.  

James Streeter is currently Global Vice President of Life Sciences Product Strategy within Oracles Health Sciences Global Business Unit. James previously held leadership roles at PPD in both operations, as the Global Head of Global Clinical Technical Operations and EDC and recently in IT, as Global Head of Systems Development, Business Operations Teams, and eClinical Strategy and Innovation. He can be reached at james.streeter@oracle.com